Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiology/Diagnostic Imaginguniverahealthcare PET Non-Oncologic Coverage Updat…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifieduniverahealthcarePolicy 6.01.07

    Positron Emission Tomography (PET) - Non-Oncologic Applications

    Customize your policy alerts

    Sign up for univerahealthcare Policy 6.01.07 alerts

    Get alerted when Policy 6.01.07 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical appropriateness criteria for PET/CT and cardiac PET perfusion imaging for non-oncologic indications (abdominal, retroperitoneal, splenic, lymphoproliferative, cardiac) affecting providers requesting or performing these studies for Univera Healthcare members.

    Policy Summary
    Payeruniverahealthcare
    PolicyPositron Emission Tomography (PET) - Non-Oncologic Applications
    Policy CodePolicy 6.01.07
    Change TypeMaterial content additions and restructuring (added AQMBF, abdominal/chest/spine indicationshead imaging moved)
    Effective DateOct 15, 2026
    Last ReviewJun 18, 2026
    Next Review DateJun 1, 2027
    Key ActionDocument medical necessity and prior imaging results when requesting PET/CT; obtain prior authorization when policy prerequisites (e.g., equivocal MRI/CT or documentation of inconclusive ETT) are present.
    SourceLink
    POLICY UPDATE CHANGES

    Added new criteria for AQMBF with PET and Stress Testing with Imaging including PET MPI.

    Abdominal imaging: Medically appropriate criteria was added for PET/CT for sclerosing mesenteritis, incidental non-diagnostic splenic findings, and retroperitoneal fibrosis.

    Chest imaging: Added indications for PET/CT for mediastinal lymphadenopathy and incidental pulmonary nodule detected by CT.

    Removed all head imaging criteria and moved it to the new PET Head Imaging Policy #6.01.47.

    Spine imaging: New medically appropriate statement for spinal infections.

    PVD imaging: Medically necessary statement added for PET/CT for initial staging in place of MRA or CTA of multiple areas when diffuse large vessel involvement.

    Removed not medically necessary statement for inflammation of cranial arteries and added new medically necessary statement for PET when MRA or ultrasound are equivocal.

    Off cycle review removed cardiac PET criteria regarding body mass, breast size or implants and exercise requirements; replaced with new criteria.

    Removed E/I (experimental/investigational) designation from radiotracers that are FDA approved.

    multipledistinct indication groups
    criteriacriteria-based
    3-6 morepeat interval (cardiac sarcoidosis)
    AQMBFAQMBF covered with PET perfusion
    >=3 moprosthetic valve post-implant interval
    part 11document part

    Coverage Criteria — Non‑Oncologic PET/CT and Cardiac PET

    Lymphoproliferative disorders

    Positron emission tomography/computed tomography (PET/CT) imaging is medically appropriate for lymphoproliferative disorders for ANY of the following indications:

    Lymphoproliferative ANY criteria: Prior to biopsy to determine a more favorable site for biopsy when a prior biopsy was nondiagnostic

    Each listed condition is sufficient (ANY).

    Lymphoproliferative ANY criteria: An inaccessible site is contemplated which would require invasive surgical intervention for biopsy attempt

    Each listed condition is sufficient (ANY).

    Lymphoproliferative ANY criteria: If biopsy is inconclusive

    Each listed condition is sufficient (ANY).

    Policy Summary
    Payeruniverahealthcare
    PolicyPositron Emission Tomography (PET) - Non-Oncologic Applications
    Policy CodePolicy 6.01.07
    Change TypeMaterial content additions and restructuring (added AQMBF, abdominal/chest/spine indicationshead imaging moved)
    Effective DateOct 15, 2026
    Last ReviewJun 18, 2026
    Next Review DateJun 1, 2027
    Key ActionDocument medical necessity and prior imaging results when requesting PET/CT; obtain prior authorization when policy prerequisites (e.g., equivocal MRI/CT or documentation of inconclusive ETT) are present.
    SourceLink
    On This Page
    Coverage Criteria — Non‑Oncologic PET/CT and Cardiac PETCovered Indications — Summary of Allowed PET UsesCoding — CPT, HCPCS, ICD-10 and Billing NotesProvider Actions — Prior Authorization, Documentation & Billing GuidanceDefinitions and Key TermsPrior Authorization Guidance and Frequency LimitsContrast and Radiotracer ConsiderationsBackground and ScopeNot Covered / Investigational IndicationsRevision History and Policy Changes

    Sclerosing mesenteritis or mesenteric panniculitis

    PET/CT imaging is medically appropriate when ALL of the following are met:

    Sclerosing mesenteritis criteria: Follow-up imaging is asymptomatic

    All conditions must be met for appropriateness.

    Sclerosing mesenteritis criteria: Sequential imaging to monitor for the development of malignancy

    All conditions must be met for appropriateness.

    Sclerosing mesenteritis criteria: Lymph nodes greater than or equal to 10 mmlymph nodes >= 10 mm

    All conditions must be met for appropriateness.

    Incidental non-diagnostic splenic findings on CT or MRI

    PET/CT imaging is medically appropriate for either of the following indication branches:

    Incidental splenic - prior imaging branch: Prior imaging is available and there is a lack of stability in findings

    One branch allowing PET when instability on prior imaging is present.

    Incidental splenic - no known malignancy branch: No known malignancy AND suspicious imaging features AND MRI abdomen is inconclusive AND biopsy is not feasible

    All sub-conditions must be met when no known malignancy.

    Retroperitoneal fibrosis

    PET/CT imaging is medically appropriate when either of the following indications are met:

    Retroperitoneal fibrosis branches: After diagnosis to establish avidity patterns to assess likelihood of malignancy and to stratify likelihood of response to steroids

    Either branch is sufficient.

    Retroperitoneal fibrosis branches: Follow-up when there is documentation that results will prompt an anticipated therapeutic change (e.g., change in immunosuppression therapy or stent removal)

    Either branch is sufficient.

    Cardiac PET perfusion imaging

    Cardiac PET perfusion imaging is considered medically appropriate for EITHER of the following indications:

    Cardiac PET criteria: Requested after an equivocal nuclear perfusion (SPECT MPI) stress test

    Either condition qualifies.

    Cardiac PET criteria: Routine post-heart transplant assessment of transplant coronary artery disease (CAD)

    Either condition qualifies.

    Cardiac PET perfusion — Either/Or indications

    Cardiac PET perfusion imaging is considered medically appropriate for EITHER of the following:

    Post-SPECT or transplant: Requested after an equivocal SPECT MPI stress test

    See policy statement.

    Post-heart transplant assessment: Routine post-heart transplant assessment of transplant coronary artery disease

    See policy statement.

    Myocardial viability

    Cardiac PET or PET-metabolic or perfusion is considered medically appropriate for ANY of the following:

    Myocardial viability: Determine myocardial viability in patients with severe left ventricular dysfunction to determine candidacy for revascularization

    Any listed criterion is sufficient.

    Cardiac sarcoidosis indications and monitoring

    Suspected cardiac sarcoidosis — any of the following scenarios:

    MRI contraindication: Initial imaging when there is a contraindication to MRI (e.g., non–MRI-safe pacemaker, renal failure)

    See cardiac sarcoidosis indications.

    MRI equivocal: Initial cardiac MRI is equivocal or additional information is needed based on MRI results

    See cardiac sarcoidosis indications.

    Confirm MRI suggestion: To confirm diagnosis if suggested by MRI

    See cardiac sarcoidosis indications.

    Known extracardiac sarcoidosis: Initial imaging to evaluate for suspected cardiac sarcoidosis when there is documented extracardiac sarcoidosis

    See cardiac sarcoidosis indications.

    Monitor therapy pre-treatment: PET with F-18 FDG metabolic study combined with a PET perfusion study prior to treatment of cardiac sarcoidosis

    See cardiac sarcoidosis monitoring.

    Monitor therapy interval: PET (heart FDG metabolic with perfusion) can be repeated at 3–6 month intervals if there is active disease or to make therapeutic decisions3-6 months

    Repeat interval for monitoring per policy.

    Approved radiotracers for cardiac indications

    Accepted radiotracers for the above cardiac PET indications:

    FDG: Fluorodeoxyglucose (FDG) is medically appropriate

    See radiotracer list.

    Rb-82: Rubidium-82 (Rb-82) is medically appropriate

    See radiotracer list.

    N-13 ammonia: Nitrogen ammonia N-13 (ammonia N-13) is medically appropriate

    See radiotracer list.

    FDG PET/CT for suspected prosthetic valve endocarditis

    FDG PET/CT for suspected prosthetic heart valve endocarditis is considered medically appropriate when ALL of the following are met:

    Echocardiography equivocal: Transthoracic or transesophageal echocardiography (TTE/TEE) are equivocal or nondiagnostic and clinical suspicion remains high

    Echocardiography must be nondiagnostic.

    CRP threshold: C-reactive protein (CRP) level greater than or equal to 40 mg/L>= 40 mg/L

    Laboratory threshold required.

    No prolonged antibiotics: No evidence of prolonged antibiotic therapy

    Absence of prolonged antibiotics must be documented.

    Time since implantation: Valve implantation was greater than or equal to 3 months ago>= 3 months

    Post-implantation interval required.

    No surgical adhesives: There is no evidence of surgical adhesives used during the valve implantation

    Absence of surgical adhesives required.

    Absolute Quantitation Of Myocardial Blood Flow (AQMBF)

    AQMBF with PET perfusion

    AQMBF considered medically appropriate: Absolute Quantitation Of Myocardial Blood Flow (AQMBF) is considered medically appropriate to further evaluate cardiac function when included with cardiac PET perfusion

    AQMBF must be performed in conjunction with cardiac PET perfusion.

    Stress Testing with Imaging (PET MPI)

    Stress testing with imaging (including PET MPI) is considered medically necessary in ANY of the following clinical settings:

    Clinical settings for medically necessary stress imaging: New, recurrent, or worsening cardiac chest pain; prior history of PCI or CABG or history of obstructive CAD with symptoms (cardiac chest pain, anginal equivalents, symptoms similar to prior ischemic episode, or new elevated troponin with known CAD after last evaluation); or new/recurrent/worsening exertional dyspnea or fatigue unexplained by another process in individuals 50 years of age or older with two or more cardiovascular risk factors (examples: diabetes, current smoking, family history of premature CAD, hypertension, hyperlipidemia, history of adverse pregnancy outcomes)

    Any listed clinical setting suffices.

    ETT Inadequacy / ECG Uninterpretable

    Reasons ETT may be inadequate or ECG uninterpretable

    ECG findings that preclude reliable ETT interpretation: Findings that may alter ECG changes during exercise or render the ECG uninterpretable for ischemia include complete left bundle branch block (LBBB) and ventricular paced rhythm

    Bifascicular block involving right bundle branch and left anterior hemiblock does not render ECG uninterpretable.

    ETT Uninterpretable ECG Exclusions

    ETT is considered not to meet medically necessary components when ANY of the following ECG findings/history are present (making exercise ECG uninterpretable for ischemia):

    Uninterpretable ECG findings: Complete left bundle branch block; ventricular paced rhythm; pre-excitation (e.g., Wolff-Parkinson-White); ST segment depression greater than or equal to 1.0 mm (not nonspecific ST/T changes); LVH with repolarization abnormalities (strain); T-wave inversion in at least two contiguous inferior and/or lateral leads; individual on digitalis

    Any listed finding renders ETT ECG uninterpretable for ischemia.

    Inconclusive ETT Criteria

    An ETT is considered inconclusive when ANY of the following occur:

    Inconclusive ETT: Failure to achieve 85% of maximum predicted heart rate; or exercise ECG becomes uninterpretable for ischemia (for example due to development of rate-related LBBB)85% MPHR

    Either condition makes ETT inconclusive.

    Abnormal ETT Findings

    Abnormal ETT results that may prompt alternative imaging include ANY of the following:

    Abnormal ETT findings: ST segment depression (horizontal or downsloping) greater than or equal to 1.0 mm; development of chest pain during exercise; drop in systolic blood pressure greater than 10 mmHg during exercise; non-sustained VT (>=3 consecutive ventricular beats at >100 bpm); sustained VT (>100 bpm lasting >30 seconds or requiring termination); coronary artery calcium (CAC) score >= 100ST >= 1.0 mm; CAC >= 100

    Any listed abnormal ETT result may prompt alternative imaging.

    Physical limitations preventing ETT

    Inability to perform adequate exercise testing (ETT) due to physical limitations:

    Physical limitations: Inability to reach target heart rate (85% MPHR) or perform >=5 METs on a treadmill due to gait disturbance, use of assistive devices, or documented neuromuscular abnormalities; use of home oxygen for daily activity; documented activity-limiting dyspnea or heart failure5 METs; 85% MPHR

    Any listed limitation may render ETT inadequate.

    AQMBF for non-obstructive CAD with persistent symptoms

    Stress imaging with AQMBF is indicated for individuals with suspected or known non-obstructive CAD (MINOCA, INOCA, ANOCA) to evaluate persistent symptoms when ANY of the following apply:

    Indications for AQMBF after non-obstructive CAD: A normal or equivocal ETT; OR a diagnosis of no obstructive CAD on CCTA or invasive coronary angiography with either persistent symptoms despite medical management (beta-blockers, calcium channel blockers, nitrates, ranolazine, ACE inhibitors) OR functional testing demonstrating myocardial ischemia

    Any listed condition supports AQMBF for persistent symptoms.

    PET for heart failure / LV dysfunction / viability assessment

    PET to evaluate heart failure or left ventricular systolic dysfunction is indicated when ANY of the following are documented:

    Heart failure/LV dysfunction indications: New or worsening heart failure; new left ventricular systolic dysfunction (LVEF < 50%); worsening LV systolic dysfunction (decline in LVEF >= 10%); significant ischemic ventricular dysfunction (suspected hibernating myocardium) when revascularization is being considered

    Any listed condition suffices for consideration of PET.

    Arrhythmia and antiarrhythmic therapy assessment

    PET is indicated for evaluation related to arrhythmia or suspected ischemic arrhythmogenic etiologies when ANY of the following are present:

    Arrhythmia-related indications: Syncope of suspected ischemic etiology not otherwise explained; sustained ventricular tachycardia (>100 bpm lasting >30 seconds or requiring termination due to hemodynamic compromise); non-sustained ventricular tachycardia (>=3 consecutive ventricular beats at >100 bpm); frequent premature ventricular complexes (PVCs) >30 PVCs per hour; prior to starting a Class IC antiarrhythmic agent (flecainide or propafenone) and annually while on the medication to assess for CAD

    Any listed indication supports PET evaluation.

    Functional assessment for moderate coronary stenosis

    To evaluate the functional significance of moderate coronary stenosis (when documentation exists):

    Moderate stenosis assessment: CCTA demonstrating moderate stenosis (50–69%, CAD-RADS 3) or invasive coronary angiography with intermediate severity stenosis when invasive physiologic testing has not been performed50-69%

    Documentation of stenosis required.

    Cardiac indications - evaluation for coronary artery disease

    Cardiac PET/CT covered when criteria are met:

    Cardiac PET indications: Functional evaluation of CAD, myocardial viability, arrhythmia assessment, and related indications as specified in policy

    See individual criteria nodes for details.

    Documentation of stenosis: To evaluate functional significance of moderate stenosis when there is documentation of either CCTA showing 50–69% stenosis (CAD-RADS 3) OR invasive coronary angiography with intermediate severity stenosis when invasive physiologic testing has not been done50-69%

    Documentation required.

    Pre-treatment and surveillance uses: PET prior to starting or annually while on Class IC antiarrhythmic agents; prior to starting certain therapies; every 2 years for history of silent ischemia; asymptomatic individuals with ischemic ECG response on ETT (horizontal or downsloping ST depression >=1.0 mm)

    See policy for surveillance intervals and specifics.

    Sarcoidosis indications

    Chest PET/CT covered when criteria are met:

    Biopsy guidance: PET/CT to guide biopsy when a known CT chest lesion is difficult to access and PET identifies an alternative biopsy location

    Also when no apparent lung involvement to identify extrapulmonary biopsy site.

    Disease characterization and management: Differentiation of reversible granulomatous disease from irreversible pulmonary fibrosis if it will affect treatment decisions; identifying treatment failure where treatment will be modified or initiated

    Either listed purpose supports PET/CT use.

    Enlarged mediastinal lymph nodes

    Mediastinal lymphadenopathy

    Size criterion: Enlarged mediastinal lymph nodes greater than or equal to 15 mm with no explainable disease or increasing size on follow-up CT chest>= 15 mm

    Size threshold required for PET consideration.

    Pulmonary nodule PET/CT

    Incidental pulmonary nodules detected on CT

    Size and composition: Solid lung nodule or solid component of a sub-solid nodule greater than or equal to 8 mm; ground-glass opacity is excluded>= 8 mm

    Ground-glass opacities are not an indicated population for PET/CT.

    Suspected bone infection (FDG PET/CT)

    Musculoskeletal PET/CT covered when criteria are met:

    Prerequisite imaging: MRI or CT is equivocal or cannot be done

    FDG PET/CT is medically appropriate when prior imaging is equivocal or not feasible.

    Indications: One of the specified indications must be present (for example, multifocal infection)

    FDG is the only indicated radiotracer for musculoskeletal PET/CT.

    FDG PET/CT for suspected bone infection

    FDG PET/CT for suspected bone infection is covered when ALL of the following are met:

    Prerequisite: MRI or CT is equivocal or cannot be done

    Required prerequisite imaging condition.

    Indications: One of the following indications must be present: infection is multifocal; infection associated with orthopedic hardware; chronic bone alterations from trauma or surgery

    Any one of these indications must be present.

    PET/CT for peripheral vascular/aortic infection

    PET/CT for peripheral vascular/aortic infection is covered when ALL of the following are met:

    Clinical suspicion of aortic infection (graft or native aorta)

    Clinical concern for aortic/graft infection required.

    Imaging prerequisite: CT-angiogram (CTA) or MRA is nondiagnostic/equivocal or cannot be done

    Prior vascular imaging must be nondiagnostic or unavailable.

    Alternative studies: Indium-111 or Gallium-67 studies have not been performed and are not available or not technically feasible

    Alternative nuclear studies should be unavailable or not feasible.

    Staging exception: PET/CT may be used for initial staging in place of MRA/CTA of multiple areas when diffuse large-vessel involvement or occult vessel involvement is suspected

    Policy allows PET/CT as initial staging alternative in specified vascular disease contexts.

    FDG-PET/CT whole body for suspected spinal infection

    FDG-PET/CT whole body for suspected spinal infection is covered when ALL of the following are met:

    Anatomic imaging: X-ray or CT are abnormal and MRI cannot be performed or is inconclusive

    Prerequisite imaging condition.

    Clinical findings: Any one of the following clinical features: fever; history of intravenous drug use; recent bacterial infection (e.g., UTI, pyelonephritis, pneumonia)

    At least one clinical risk factor or sign is required.

    PET for initial staging of vascular disease

    Staging in lieu of MRA/CTA: PET/CT for initial staging in place of MRA or CTA of multiple areas when diffuse large vessel involvement or occult vessel involvement is suspected

    Single top-level indication for vascular staging.

    Temporal artery / GCA

    Temporal artery / GCA

    Equivocal prior testing: MRA or ultrasound are equivocal and temporal artery biopsy is negative with continued suspicion for giant cell arteritis

    Where results would change clinical management.

    Impact on management: Results are expected to change clinical management

    PET considered when management decisions depend on imaging.

    Spinal infection indications

    FDG-PET/CT whole body is medically appropriate when ALL of the following are met:

    Prerequisites: (1) Clinical suspicion of spinal infection; (2) X-ray or CT are abnormal; (3) MRI cannot be performed or is inconclusive

    All prerequisites must be met before accepting clinical risk factors.

    Acceptable clinical contexts (any one suffices): History of intravenous drug use; recent bacterial infection; recent spinal intervention; immunocompromised state; long-term systemic glucocorticoid use; organ transplant on anti-rejection medication; diabetes mellitus; HIV/AIDS; chronic dialysis; immunosuppressant therapy; neoplastic involvement of the spine; laboratory values indicative of infection (e.g., elevated WBC, ESR, CRP, positive cultures); decubitus ulcer or wound overlying spine; abnormal x-ray or CT suspicious for infection

    Any single listed clinical context meets this branch when prerequisites are present.

    Musculoskeletal indications

    Covered when criteria below are met:

    Musculoskeletal PET/CT: PET/CT is indicated for imaging certain musculoskeletal conditions when MRI or CT is equivocal or cannot be performedMRI/CT equivocal or not possible

    FDG is the only indicated radiotracer for musculoskeletal PET/CT.

    Cardiac AQMBF / MBFR

    AQMBF (cardiac MBF quantification) coverage considerations:

    AQMBF performance requirements: AQMBF should be performed only in accredited laboratories with board-certified interpreting physicians experienced in AQMBF; laboratories must have standard protocolsaccreditation and physician qualifications required

    Supports diagnosis and prognosis of coronary artery disease and endothelial dysfunction.

    Reporting requirements: Reports should include rest and stress myocardial blood flow in ml/g/min and myocardial blood flow reserve (ratio of stress to rest) and include RPP-corrected values where applicableN/A

    Per professional society guidance.

    No explicit modality or indication exclusions are listed in this portion of the policy extract; additional exclusions or clarifying statements may appear elsewhere in the full policy document. This section should not be interpreted as a comprehensive list of exclusions for all PET/CT uses.

    For FDG PET/CT performed to evaluate suspected prosthetic heart valve endocarditis, documentation must show no evidence of surgical adhesives used during the valve implantation. Cases with documented adhesive use are specifically called out and may alter appropriateness determinations.

    The prosthetic valve endocarditis criteria explicitly require documentation that no surgical adhesives were used at the time of valve implantation; the absence of adhesives is therefore an explicit condition for considering PET in this indication.

    The policy clarifies that nonspecific ST/T wave changes are not included in the threshold for ischemic ST depression; only ST segment depression of ≥ 1.0 mm (horizontal or downsloping) meets the criterion for an abnormal exercise ECG.

    Stress testing (exercise or pharmacologic) is not appropriate in settings of significant safety risk. The policy lists unstable angina or concern for acute coronary syndrome, recent elevated troponin, severe aortic valve disease (e.g., severe aortic stenosis), and uncontrolled severe hypertension as exclusions because they preclude safe stress testing and therefore exclude stress PET in those circumstances.

    Incidental pulmonary nodules described as ground-glass opacity are excluded from the PET/CT indication for incidental nodules. PET/CT is considered only for solid nodules or a solid component of a sub-solid nodule measuring ≥ 8 mm.

    PET imaging for pelvic evaluation of impotence/erectile dysfunction is designated investigational in this policy and therefore is not a covered indication.

    The policy states that PET/CT is not medically appropriate for the evaluation of Gaucher disease; requests for PET/CT for this condition are not supported by the documented criteria.

    The policy specifies that routine PET/CT for surveillance or assessment of non-neoplastic spinal disorders—such as routine assessment after fusions or unsuccessful spine surgery—is not medically appropriate. PET/CT is only indicated for suspected spinal infection when the listed imaging and clinical prerequisites are met.

    The policy cautions billing practices: CPT codes 76376 and 76377 (3D rendering) should not be billed in conjunction with PET imaging and doing so may lead to denial or billing edits.

    The HCPCS entry for S8085 is flagged as (E/I) (experimental/investigational) in the policy's HCPCS list. Experimental or investigational items designated in this manner may not be covered under the policy.

    Coverage determinations are product-dependent. If a product does not cover a service, the policy criteria do not apply; where a product does provide coverage, the medical policy criteria described in this document apply to the benefit and should be used for prior authorization and adjudication decisions.

    Covered Indications — Summary of Allowed PET Uses

    Lymphoproliferative disorders — covered indication summary

    Positron emission tomography/computed tomography (PET/CT) imaging is medically appropriate for lymphoproliferative disorders for ANY of the following indications:

    Lymphoproliferative ANY criteria: Prior to biopsy to determine a more favorable site for biopsy when a prior biopsy was nondiagnostic

    Each listed condition is sufficient (ANY).

    Lymphoproliferative ANY criteria: An inaccessible site is contemplated which would require invasive surgical intervention for biopsy attempt

    Each listed condition is sufficient (ANY).

    Lymphoproliferative ANY criteria: If biopsy is inconclusive

    Each listed condition is sufficient (ANY).

    Sclerosing mesenteritis / mesenteric panniculitis — covered indication summary

    PET/CT imaging is medically appropriate when ALL of the following are met:

    Sclerosing mesenteritis criteria: Follow-up imaging is asymptomatic

    All conditions must be met for appropriateness.

    Sclerosing mesenteritis criteria: Sequential imaging to monitor for the development of malignancy

    All conditions must be met for appropriateness.

    Sclerosing mesenteritis criteria: Lymph nodes greater than or equal to 10 mmlymph nodes >= 10 mm

    All conditions must be met for appropriateness.

    Incidental non-diagnostic splenic findings — covered indication branches

    PET/CT imaging is medically appropriate for either of the following indication branches:

    Incidental splenic - prior imaging branch: Prior imaging is available and there is a lack of stability in findings

    One branch allowing PET when instability on prior imaging is present.

    Incidental splenic - no known malignancy branch: No known malignancy AND suspicious imaging features AND MRI abdomen is inconclusive AND biopsy is not feasible

    All sub-conditions must be met when no known malignancy.

    Retroperitoneal fibrosis — covered indication summary

    PET/CT imaging is medically appropriate when either of the following indications are met:

    Retroperitoneal fibrosis branches: After diagnosis to establish avidity patterns to assess likelihood of malignancy and to stratify likelihood of response to steroids

    Either branch is sufficient.

    Retroperitoneal fibrosis branches: Follow-up when there is documentation that results will prompt an anticipated therapeutic change (e.g., change in immunosuppression therapy or stent removal)

    Either branch is sufficient.

    Cardiac PET perfusion — covered indication summary

    Cardiac PET perfusion imaging is considered medically appropriate for EITHER of the following indications:

    Cardiac PET criteria: Requested after an equivocal nuclear perfusion (SPECT MPI) stress test

    Either condition qualifies.

    Cardiac PET criteria: Routine post-heart transplant assessment of transplant coronary artery disease (CAD)

    Either condition qualifies.

    Cardiac PET and FDG PET/CT appropriate use

    Cardiac PET and FDG PET/CT appropriate use — multiple top-level nodes:

    Post-SPECT or transplant: Cardiac PET perfusion imaging after equivocal SPECT MPI or for routine post-heart transplant CAD assessment

    See policy statements.

    Myocardial viability: Use PET to determine myocardial viability in severe LV dysfunction when considering revascularization

    See policy statements.

    Cardiac sarcoidosis: Initial imaging or monitoring for suspected cardiac sarcoidosis per listed scenarios

    See cardiac sarcoidosis nodes.

    Prosthetic valve endocarditis: FDG PET/CT when TTE/TEE equivocal, CRP >=40 mg/L, no prolonged antibiotics, implantation >=3 months, and no surgical adhesives

    AQMBF with cardiac PET perfusion — covered when performed with PET perfusion

    AQMBF with cardiac PET perfusion — covered when performed with PET perfusion:

    AQMBF indication: Absolute Quantitation Of Myocardial Blood Flow (AQMBF) is considered medically appropriate when included with cardiac PET perfusion to further evaluate cardiac function

    Must be performed with PET perfusion and by accredited labs per reporting requirements.

    Stress testing with imaging including PET MPI — covered settings

    Stress testing with imaging including PET MPI — covered settings:

    Indications for stress imaging: New/recurrent/worsening cardiac chest pain; prior PCI/CABG or known obstructive CAD with symptoms; unexplained recurrent/worsening exertional dyspnea or fatigue in individuals >=50 years with two or more cardiovascular risk factors

    Risk factors enumerated in policy.

    When ETT is inadequate, inconclusive, or abnormal — consider PET

    When ETT is inadequate, inconclusive, or abnormal as specified, consider alternative stress imaging such as PET.

    ETT inadequate/inconclusive/abnormal indications: ECG-interfering conditions (complete LBBB, ventricular paced rhythm, pre-excitation, ST depression >=1.0 mm, LVH with strain, T-wave inversion in >=2 contiguous inferior/lateral leads, digitalis use); inconclusive ETT (failure to reach 85% MPHR or exercise ECG becomes uninterpretable); abnormal ETT results (ST depression >=1.0 mm, chest pain, systolic BP drop >10 mmHg, non-sustained/sustained VT, CAC >=100); inability to perform exercise due to gait disturbance, assistive device use, home oxygen, or activity-limiting dyspnea/heart failurevarious

    When any of these are present, alternative stress imaging including PET is indicated.

    Stress PET with AQMBF for suspected/known non-obstructive CAD

    Stress PET with AQMBF for suspected/known non-obstructive CAD with persistent symptoms:

    AQMBF indications: Normal or equivocal ETT; diagnosis of no obstructive CAD on CCTA or invasive angiography with persistent symptoms despite medical therapy; or functional testing demonstrating ischemia

    Used to evaluate persistent symptoms with AQMBF.

    PET for evaluation of heart failure, LV dysfunction, and viability

    PET for evaluation of heart failure, LV dysfunction, and viability — covered when documented:

    Heart failure/viability indications: New or worsening heart failure; new LVEF <50%; decline in LVEF >=10%; suspected hibernating myocardium when revascularization is being considered

    Any listed documentation supports PET for evaluation.

    PET for arrhythmia evaluation and pre-/on-therapy Class IC assessment

    PET for arrhythmia evaluation and CAD assessment related to Class IC antiarrhythmics — covered when any are present:

    Arrhythmia and antiarrhythmic assessment: Syncope of suspected ischemic etiology; sustained VT; non-sustained VT (>=3 beats at >100 bpm); frequent PVCs >30/hour; prior to starting Class IC antiarrhythmics and annually while on therapy

    Indications listed in policy.

    Sarcoidosis — biopsy guidance and treatment monitoring

    Sarcoidosis — chest PET/CT guidance for biopsy and management:

    Biopsy guidance: PET/CT to guide biopsy when a CT chest lesion is difficult to access or when no apparent lung involvement exists to identify an extrapulmonary biopsy site

    Used to select alternative biopsy locations.

    Disease characterization/management: Differentiate reversible granulomatous disease from irreversible pulmonary fibrosis when it will affect treatment; identify treatment failure when results will change therapy

    Either purpose supports PET/CT use.

    Suspected bone infection — covered indication summary

    Suspected bone infection — covered indication summary:

    Bone infection prerequisites: MRI or CT is equivocal or cannot be done AND one of specified indications is present (for example, multifocal infection)

    FDG PET/CT appropriate when prior imaging equivocal and specific indications exist.

    Bone infection indications: Multifocal infection; infection associated with orthopedic hardware; chronic bone alterations from trauma or surgery

    Any one of these indications may justify FDG PET/CT when prerequisites met.

    Coding — CPT, HCPCS, ICD-10 and Billing Notes

    Billing cautionsCPTNot Covered
    763763D rendering
    763773D rendering, each additional
    Code modifiers/labels used in policymixed
    (E/I)Experimental/Investigational
    (NMN)Not medically necessary/appropriate
    Covered CPT CodesCPTCovered
    78429Myocardial imaging, PET, metabolic evaluation study; with concurrently acquired CT transmission scan
    78430Myocardial imaging, PET, metabolic evaluation study; single study, at rest or stress, with concurrently acquired CT transmission scan
    78811PET imaging; limited area (e.g., chest, head/neck)
    78812PET imaging; skull base to mid-thigh whole body
    78813PET imaging; skull base to mid-thigh
    78814PET with concurrently acquired CT for attenuation correction and anatomical localization; limited area
    78815PET with concurrently acquired CT for attenuation correction and anatomical localization; skull base to mid-thigh
    78816PET with concurrently acquired CT for attenuation correction and anatomical localization; whole body
    Radiopharmaceutical HCPCS CodesHCPCSCovered
    A9526Nitrogen N-13 ammonia, diagnostic, per study dose, up to 40 millicuries
    A9552Fluorodeoxyglucose F-18 (FDG), diagnostic, per study dose, up to 45 millicuries
    A9555Rubidium Rb-82, diagnostic, per study dose, up to 60 millicuries
    A9586Florbetapir F18, diagnostic, per study dose, up to 10 millicuries
    A9598PET radiopharmaceutical, diagnostic, for non-tumor identification, not otherwise classified
    A9601Flortaucipir f 18 injection, diagnostic, 1 millicurie
    A9602Fluorodopa f-18, diagnostic, per millicurie
    Q9982Flutemetamol F18, diagnostic, per study dose, up to 5 millicuries
    Q9983Florbetaben F18, diagnostic, per study dose, up to 8.1 millicuries
    S8085Fluorine-18 FDG imaging using dual-head coincidence (E/I)
    Relevant ICD-10 CodesICD-10
    D33.0-D33.9Benign neoplasm of brain and other parts of central nervous system (code range)
    D43.0-D43.9Neoplasm of uncertain behavior of brain and central nervous system (code range)
    I25.10-I25.119Atherosclerotic heart disease of native coronary artery with or without angina pectoris (code range)
    I25.700-I25.739Atherosclerosis of autologous or nonautologous vein or artery coronary artery bypass graft(s) with angina pectoris (code range)
    I25.790-I25.799Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris (code range)
    I25.810Atherosclerosis of coronary artery bypass graft(s) without angina pectoris
    I51.9Heart disease, unspecified
    I52Other heart disorders in diseases classified elsewhere
    K65.4Sclerosing mesenteritis
    M86.30-M86.69Chronic osteomyelitis (code range)
    FDG PET/CT — Prosthetic valve endocarditis thresholds
    C-reactive protein (CRP) threshold>= 40 mg/L
    Echocardiography requirementTransthoracic or transesophageal echocardiography (TTE/TEE) must be equivocal or nondiagnostic
    Antibiotic therapy considerationNo evidence of prolonged antibiotic therapy present
    Time since valve implantation for prosthetic valve endocarditis PET
    Minimum post-implantation interval>= 3 months since valve implantation
    Surgical adhesive exclusionNo evidence of surgical adhesives used during valve implantation (presence may alter appropriateness)
    Documentation requirementTiming of device implantation should be documented
    Post-implantation interval (note)
    Post-implantation interval (duplicate)>= 3 months
    RelevanceRequired as part of ALL criteria for FDG PET/CT for suspected prosthetic valve endocarditis
    Denial riskStudies may be denied if implantation <3 months
    Age and cardiovascular risk factor threshold for stress testing
    Age and cardiovascular risk thresholdIndividuals 50 years of age or above with >= 2 cardiovascular risk factors
    Examples of CV risk factorsDiabetes, current cigarette smoking, family history of premature CAD, hypertension, hyperlipidemia, history of adverse pregnancy outcomes
    Clinical contextUsed to define need for stress testing with imaging (including PET MPI) for unexplained exertional symptoms
    Maximum predicted heart rate target (ETT)
    Maximum predicted heart rate target for inconclusive ETTFailure to achieve 85% of maximum predicted heart rate (MPHR)
    Inconclusive ETT exampleExercise ECG becomes uninterpretable (e.g., development of rate-related LBBB)
    Documentation notePrior authorization/clinical documentation should indicate failure to reach 85% MPHR when claiming inconclusive ETT
    ST segment depression threshold
    ST segment depression threshold>= 1.0 mm (horizontal or downsloping)
    ExclusionNonspecific ST/T wave changes are not included in this criterion
    ETT impactST depression >=1.0 mm renders exercise ECG uninterpretable or abnormal, prompting alternative imaging
    Coronary artery calcium (CAC) score threshold
    Coronary artery calcium (CAC) score threshold>= 100
    Clinical implicationCAC >=100 listed among abnormal ETT findings that may prompt alternative imaging
    Prior authorization noteCAC >=100 may be referenced when determining need for PET after inconclusive/abnormal ETT
    Left ventricular ejection fraction (LVEF) thresholds
    LVEF threshold — new dysfunctionLeft ventricular ejection fraction (LVEF) < 50%
    LVEF threshold — worseningDecline in LVEF >= 10% compared with prior measurement
    UseIndication for PET evaluation of heart failure, LV dysfunction, or myocardial viability
    Moderate coronary stenosis definition (CAD-RADS 3)
    Definition of moderate coronary stenosis (CAD-RADS 3)50 to 69% stenosis on CCTA
    Use caseDocumentation of CCTA 50–69% may prompt PET to evaluate functional significance
    Alternative documentationInvasive coronary angiography with intermediate stenosis when invasive physiologic testing not performed
    Pulmonary nodule size threshold for PET/CT
    Pulmonary nodule size threshold for PET consideration>= 8 mm solid nodule or solid component of a sub-solid nodule
    ExclusionGround-glass opacity nodules are excluded from this PET indication
    ContextApplies to incidental pulmonary nodules detected on CT
    Mediastinal lymph node size threshold
    Mediastinal lymph node enlargement threshold>= 15 mm
    RequirementNo explainable disease or increasing size on follow-up CT chest
    IndicationEnlarged mediastinal lymph nodes meeting this size criterion are indications for PET/CT

    Provider Actions — Prior Authorization, Documentation & Billing Guidance

    Prior Authorization

    Prior authorization guidance

    Policy establishes medical necessity criteria that payers may use for prior authorization decisions for PET non-oncologic studies; specific code-level prior authorization requirements are not listed in this portion of the document.

    Prior Authorization

    Repeat interval for cardiac sarcoidosis monitoring

    PET (FDG metabolic with perfusion) for monitoring cardiac sarcoidosis may be repeated at intervals of 3–6 months if there is active disease or to inform therapeutic decisions.

    Prior Authorization

    AQMBF must accompany cardiac PET perfusion

    Absolute quantitation of myocardial blood flow (AQMBF) is considered medically appropriate only when performed in conjunction with cardiac PET perfusion.

    Prior Authorization

    ETT findings that trigger prior authorization

    Prior authorization considerations should reference specified abnormal or inconclusive ETT results such as failure to achieve 85% of maximum predicted heart rate, exercise ECG becoming uninterpretable (e.g., rate‑related LBBB), ST segment depression ≥ 1.0 mm, non‑sustained or sustained ventricular tachycardia, or CAC score ≥ 100.

    Prior Authorization

    Prior auth for pre-Class IC antiarrhythmic assessment

    PET to assess for coronary artery disease is indicated prior to initiating a Class IC antiarrhythmic (flecainide or propafenone) and annually while on the medication; prior authorization may be required per plan rules.

    Prior Authorization

    Prior auth for bone infection PET/CT after equivocal MRI/CT

    Prior authorization is required when FDG PET/CT is ordered for suspected bone infection only after MRI or CT are equivocal or cannot be performed and one of the specified indications (e.g., multifocal infection, hardware‑associated infection) is present.

    Prior Authorization

    Prior authorization for vascular PET/CT indications

    Prior authorization is expected when PET/CT is requested as an alternative to nondiagnostic MRA/CTA or when PET/CT is used for initial staging in place of MRA/CTA for suspected diffuse large‑vessel involvement.

    Prior Authorization

    Prior authorization recommended for spinal infection PET/CT

    Prior authorization is recommended for whole‑body FDG‑PET/CT in suspected spinal infection; requests should document that MRI cannot be performed or is inconclusive and include listed risk factors or abnormal x‑ray/CT findings.

    Prior Authorization

    Prior authorization for musculoskeletal PET/CT when MRI/CT equivocal

    PET/CT for select musculoskeletal indications is indicated only when MRI or CT are equivocal or cannot be performed; prior authorization is required per payer rules for these non‑oncologic musculoskeletal PET/CT studies.

    Billing Rule

    Confirm authorization for listed PET codes

    Coverage for the listed PET CPT and HCPCS codes may require prior authorization depending on circumstances; providers should confirm coverage/authorization requirements before performing services.

    • Codes listed in policy include 78811–78816, 78429–78430 and HCPCS A9526–Q9983, S8085.
    Prior Authorization

    Verify Medicare and local coverage decisions

    If a Medicare product covers a service and there is no national or local Medicare coverage decision for the service, medical policy criteria apply; verify Medicare/local coverage and product terms prior to authorization.

    Note

    Ensure imaging will change management

    Appropriateness of PET imaging often depends on whether the result will change management; obtain and document that the requested PET study will affect therapeutic or diagnostic decisions.

    Step Therapy

    Use cardiac PET after equivocal SPECT MPI

    Cardiac PET perfusion may be used after an equivocal SPECT myocardial perfusion (SPECT MPI) stress test as an alternative imaging modality.

    Documentation Required

    ETT component failures that justify imaging

    Document ECG‑interfering conditions (e.g., complete left bundle branch block or ventricular paced rhythm) that make exercise treadmill testing inadequate or uninterpretable prior to requesting PET.

    Step Therapy

    Document inability to exercise before stepping to alternatives

    Providers should document inability to perform exercise (for example due to gait disturbance or need for assistive device) before proceeding to pharmacologic stress testing or imaging alternatives such as PET.

    Step Therapy

    Stepwise evaluation required before AQMBF PET

    Before performing AQMBF PET for suspected/known non‑obstructive CAD, demonstrate a normal/equivocal ETT or diagnostic uncertainty after other testing per the stepwise evaluation rules.

    Step Therapy

    Prior imaging required before bone infection PET/CT

    Require prior use or consideration of MRI or CT before FDG PET/CT for suspected bone infection unless those modalities are equivocal or contraindicated.

    Documentation Required

    Required documentation of prior imaging attempts

    Document that nondiagnostic or unavailable MRA/CTA (and where relevant indium‑111 or gallium‑67 studies) were attempted or not feasible before approving PET/CT for vascular infection or staging in place of MRA/CTA.

    Step Therapy

    Imaging pathway: prefer MRI/CT before FDG‑PET/CT

    Consider MRI or CT first; FDG‑PET/CT is indicated when x‑ray or CT are abnormal and MRI cannot be performed or is inconclusive.

    Documentation Required

    AQMBF accreditation and qualified personnel required

    AQMBF should be performed only in accredited laboratories with board‑certified interpreting physicians experienced in AQMBF using standardized protocols; reports must include rest and stress MBF (ml/g/min) and MBFR (ratio of stress to rest) and RPP‑corrected values where applicable.

    • Laboratory accreditation: IAC, ACR, or Joint Commission cardiac PET accredited.
    • Interpreting physician board certification in Nuclear Cardiology, Nuclear Medicine, or Radiology with AQMBF training.
    • Standardized protocols and reporting of MBF/MBFR and RPP‑corrected values.
    Note
    Note
    Documentation Required

    Supporting imaging/biopsy documentation for incidental splenic findings

    When PET/CT is requested for incidental splenic findings, prior imaging and documentation that MRI was inconclusive or biopsy is not feasible must be provided to support the request.

    Documentation Required

    Echocardiography equivocal documentation for prosthetic valve PET

    Documentation should demonstrate that transthoracic or transesophageal echocardiography was equivocal or nondiagnostic and that clinical suspicion for prosthetic valve endocarditis remains high before ordering FDG PET/CT.

    Documentation Required

    Document device timing and surgical adhesive absence for prosthetic valve PET

    Document timing of valve or device implantation (implantation ≥ 3 months ago) and absence of surgical adhesives used during implantation when seeking FDG PET/CT for prosthetic valve endocarditis.

    • Implantation date showing ≥ 3 months since procedure.
    • Statement that no surgical adhesives were used during the implantation.
    Documentation Required

    Document ETT inconclusive details (e.g., <85% MPHR)

    When seeking PET due to an inconclusive ETT, document specific details such as failure to reach 85% of maximum predicted heart rate or exercise ECG becoming uninterpretable (e.g., development of rate‑related LBBB).

    • Record achieved % of MPHR and reason ETT was inconclusive.
    Documentation Required

    Required clinical documentation for stress PET

    Clinical documentation supporting stress PET should include use of home oxygen for daily activity, activity‑limiting dyspnea or heart failure, and the provider’s assessment that exercise testing is unsafe or inadequate.

    Documentation Required

    Coronary imaging documentation for PET functional assessment

    To support PET for functional assessment of moderate coronary stenosis, provide coronary imaging showing CCTA with 50–69% stenosis (CAD‑RADS 3) or invasive angiography with intermediate lesions when invasive physiologic testing has not been performed.

    Documentation Required

    Imaging pathway documentation showing prior modalities nondiagnostic/unavailable

    Documentation should demonstrate that prior imaging modalities (MRI, CT, MRA, CTA) were equivocal/indeterminate or could not be performed and indicate the specific clinical indication for PET (e.g., multifocal bone infection, hardware‑associated infection, suspected aortic infection).

    Documentation Required

    Clinical justification for spinal infection PET

    Clinical justification for spinal infection PET must include clinical suspicion plus at least one listed risk factor or laboratory marker of infection (e.g., fever, IV drug use, recent bacterial infection, elevated WBC/ESR/CRP, positive cultures) and abnormal x‑ray or CT when MRI cannot be done or is inconclusive.

    Documentation Required

    AQMBF reporting requirements (rest/stress MBF and MBFR)

    AQMBF reports must include rest MBF and stress MBF in ml/g/min and myocardial blood flow reserve (MBFR, ratio of stress to rest MBF); laboratories should also report RPP‑corrected resting MBF and MBFR where applicable.

    Billing Rule

    Coding documentation: use policy CPT/HCPCS descriptors

    Use the CPT and HCPCS code descriptors listed in the policy when submitting claims for PET procedures and radiopharmaceuticals to support billing and authorization.

    Documentation Required

    Confirm member product covers the service

    Confirm that the member’s product covers the requested PET service before applying medical policy criteria, as policy criteria apply only when the product covers the service.

    Denial Risk

    Denial risk for unmet policy criteria

    Requests that fail to meet any of the indication‑specific criteria listed in the policy (for example, none of the ANY or ALL conditions for lymphoproliferative, sclerosing mesenteritis, incidental splenic findings, or cardiac PET indications) are at risk of being found not medically appropriate and denied.

    Denial Risk

    Prosthetic valve PET criteria required to avoid denial

    FDG PET/CT for suspected prosthetic valve endocarditis is contingent on meeting criteria including echocardiography equivocal/nondiagnostic, CRP ≥ 40 mg/L, no evidence of prolonged antibiotic therapy, implantation ≥ 3 months ago, and no evidence of surgical adhesives used during implantation.

    Denial Risk

    LVAD driveline infection unsupported—denial risk

    Studies for suspected LVAD driveline infection may be denied if other studies and physical examination are inconclusive and do not support the diagnosis.

    Denial Risk

    ETT‑precluding ECG findings (document to justify PET)

    Uninterpretable ECG findings that preclude an adequate ETT include complete left bundle branch block, ventricular paced rhythm, pre‑excitation (e.g., WPW), ST segment depression ≥ 1.0 mm (not nonspecific ST/T changes), LVH with repolarization abnormalities, T‑wave inversion in ≥2 contiguous inferior/lateral leads, or digitalis therapy; document these when relying on ECG non‑interpretability.

    Documentation Required

    Document physical limitations preventing ETT

    Physical limitations that may prevent adequate ETT—such as gait disturbance, use of assistive devices, neuromuscular abnormalities, need for home oxygen, or activity‑limiting dyspnea/heart failure—should be documented to support alternative stress imaging.

    Denial Risk

    Safety‑related denial risks for stress testing

    Requests for stress testing may be denied for safety reasons in patients with unstable angina or concern for acute coronary syndrome, recent elevated troponin, severe aortic valve disease, or uncontrolled severe hypertension.

    Denial Risk

    Pulmonary nodule size threshold—denial risk for <8 mm/ground‑glass

    PET is not supported for incidental solid pulmonary nodules smaller than 8 mm or for ground‑glass opacities; requests outside the ≥ 8 mm solid nodule criterion may be denied.

    Denial Risk

    Investigational indication: impotence/erectile dysfunction

    PET imaging for impotence/erectile dysfunction is considered investigational and will be denied.

    Denial Risk

    Not medically appropriate: Gaucher disease

    PET/CT for evaluation of Gaucher disease is considered not medically appropriate and may be denied.

    Denial Risk

    Routine spinal assessment excluded—denial risk

    Routine PET/CT for assessment of spinal disorders, fusions, or unsuccessful spine surgery other than neoplastic disease is not medically appropriate and may be denied.

    Billing Rule

    Do not bill CPT 76376/76377 with PET

    Do not bill 3D rendering codes (CPT 76376 or 76377) in conjunction with PET imaging; such billing may trigger denial.

    Denial Risk

    Coverage conditionality—codes may not be covered in all circumstances

    Coverage for codes listed in the policy may be conditional and not covered in all circumstances; verify code‑level coverage before proceeding.

    Documentation Required

    Product‑dependent coverage—verify member product

    Confirm the member’s product covers the service; medical policy criteria apply only when the product covers the service and lack of coverage may lead to denial.

    Definitions and Key Terms

    PET/CT imaging (non-oncologic) — definition and scope summary
    Definition: PET/CT imaging (non-oncologic)Positron emission tomography with or without CT used to evaluate metabolic activity for non-cancer conditions (e.g., lymphoproliferative disorders, sclerosing mesenteritis, incidental splenic lesions, retroperitoneal fibrosis, cardiac perfusion)
    ScopeIncludes FDG metabolic studies and cardiac PET perfusion (MPI) as described in policy
    PurposeUsed when conventional anatomic imaging or biopsy is nondiagnostic or infeasible and when results will change management
    Myocardial viability — definition for PET viability testing
    Myocardial viability — definition for PET viability testingPET (metabolic or perfusion) is used to determine myocardial viability in patients with severe left ventricular dysfunction to assess candidacy for revascularization
    Clinical triggerConsider when LVEF <50% or suspected hibernating myocardium with potential for revascularization
    TechniqueMay use dual radiotracer approaches including metabolic and perfusion PET studies
    Cardiac sarcoidosis indications — definition/uses
    Cardiac sarcoidosis indications — definition/usesInitial imaging when MRI is contraindicated or equivocal, to confirm MRI-suggested diagnosis, to evaluate known extracardiac sarcoidosis, and for therapy monitoring
    Monitoring intervalPET (FDG metabolic with perfusion) can be repeated at 3–6 month intervals for active disease or to inform therapy decisions
    Required componentsFDG metabolic study combined with a PET perfusion study for monitoring
    AQMBF — definition and role with cardiac perfusion PET
    AQMBF — definition and role with cardiac perfusion PETAbsolute quantitation of myocardial blood flow (AQMBF) measures rest and stress MBF (ml/g/min) and MBF reserve (stress/rest); used to further evaluate cardiac function when included with cardiac PET perfusion
    Performance requirementsShould be performed only in accredited laboratories by board‑certified physicians with standardized protocols
    Reporting requirementsReports must include rest and stress MBF in ml/g/min and MBF reserve; RPP-corrected values when applicable
    ECG-uninterpretable for ischemia — list of interfering ECG findings
    ECG-uninterpretable for ischemia — interfering findings listComplete left bundle branch block; ventricular paced rhythm; pre-excitation (e.g., WPW); LVH with repolarization abnormalities; T-wave inversion in >=2 contiguous inferior/lateral leads; digitalis use
    ImplicationPresence of these findings renders the exercise ECG uninterpretable and supports alternative stress imaging
    ClarificationBifascicular block involving RBBB and left anterior hemiblock does not render ECG uninterpretable
    Maximum predicted heart rate (MPHR) — definition and use (85% threshold referenced elsewhere)
    MPHR — definition and useMaximum predicted heart rate (MPHR) used as target for exercise testing; 85% MPHR is commonly applied as threshold for adequate stress
    ApplicationFailure to achieve 85% MPHR defines an inconclusive ETT and may prompt alternative imaging such as PET
    DocumentationProviders should document failure to reach 85% MPHR when requesting PET for inconclusive ETT
    Ventricular tachycardia definitions — non-sustained vs sustained VT thresholds
    Ventricular tachycardia definitionsNon‑sustained VT: >=3 consecutive ventricular beats at >100 bpm; Sustained VT: >100 bpm lasting >30 seconds or requiring termination due to hemodynamic compromise
    Non‑sustained numeric threshold>=3 beats at >100 bpm
    Sustained VT duration threshold>30 seconds (or requiring termination)
    LVEF < 50% — definition for new LV systolic dysfunction
    Definition: new LV systolic dysfunctionLeft ventricular ejection fraction < 50%
    Clinical useThreshold triggers PET evaluation for heart failure and viability
    Related thresholdWorsening defined as decline >=10% in LVEF
    Non-sustained VT numeric definition
    Non‑sustained VT numeric definition>= 3 consecutive ventricular beats at >100 bpm
    ContextListed among abnormal ETT findings that may prompt alternative imaging
    Relation to sustained VTDistinguished from sustained VT (>30 seconds) which has separate criteria
    Moderate coronary stenosis — CAD-RADS 3 definition referencing 50-69% stenosis
    Moderate coronary stenosis (CAD-RADS 3) definition50–69% stenosis
    ContextCCTA demonstrating 50–69% (CAD-RADS 3) may prompt PET to evaluate functional significance
    DocumentationEither CCTA or invasive angiography demonstrating intermediate stenosis supports PET use
    Incidental solid pulmonary nodule — >=8 mm solid component required; ground-glass excluded
    Incidental solid pulmonary nodule definitionSolid lung nodule or solid component of a sub-solid nodule >= 8 mm (ground‑glass excluded)
    ApplicationSize and solid composition threshold used to consider PET/CT for incidental nodules
    ExclusionGround‑glass opacities are not an indicated population for PET/CT per policy
    Multifocal infection definition — whole-body PET/CT use case
    Multifocal infection — definition/useInfection involving multiple, noncontiguous skeletal or vascular sites where whole‑body FDG‑PET/CT may identify additional foci
    IndicationOne of the specific indications that supports FDG PET/CT for suspected bone infection when MRI/CT are equivocal or not feasible
    ModalityWhole‑body FDG PET/CT
    Clinical suspicion of spinal infection — signs and context
    Clinical suspicion of spinal infection — supporting signsFever; history of IV drug use; recent bacterial infection (e.g., UTI, pyelonephritis, pneumonia)
    ContextRequired along with abnormal x‑ray/CT and inability to perform or inconclusive MRI to justify whole‑body FDG‑PET/CT
    Use casePart of the ANY list where any one listed risk factor suffices when prerequisites met
    FDG-PET/CT whole body — definition
    FDG‑PET/CT whole body — definitionWhole‑body FDG PET/CT performed when x‑ray/CT abnormal and MRI cannot be performed or is inconclusive, with supporting clinical signs or lab evidence
    ScopeUsed to detect multifocal infection or identify additional infectious foci across body regions
    PrerequisitesAbnormal x‑ray/CT plus inability to perform or inconclusive MRI and presence of listed clinical risk factors
    PET — generic definition
    PET — generic definitionImaging modality that reveals metabolic information using positron‑emitting radiotracers (e.g., FDG, rubidium‑82, ammonia N‑13) to assess tissue viability and metabolic activity
    DistinctionProvides metabolic, not just anatomic, information compared with MRI/CT
    Tracer noteMany tracers require on‑site cyclotron except fluorine‑18 and rubidium
    AQMBF / MBFR — definition and calculation
    AQMBF / MBFR — definition and calculationAQMBF measures rest and stress myocardial blood flow in ml/g/min and calculates myocardial blood flow reserve (MBFR) as stress/rest ratio
    Clinical valueUsed for diagnosis and prognosis of CAD and endothelial dysfunction (e.g., diabetes, LVH, transplant vasculopathy)
    ReportingReports should include rest and stress MBF and MBFR; RPP‑corrected values where applicable
    CPT PET procedure codes — definition / list reference
    CPT PET procedure codes — scopeIncludes myocardial PET codes (78429, 78430) and PET imaging/attenuation/localization codes (78811–78816)
    UseCodes listed in policy correspond to covered PET procedures referenced in coverage rules
    ReferenceDetailed code descriptors are provided in the policy CPT section
    Radiopharmaceutical HCPCS codes — definition / list reference
    Radiopharmaceutical HCPCS codes — examplesIncludes A9526 (N‑13 ammonia), A9552 (FDG F‑18), A9555 (Rb‑82), and others listed in the policy HCPCS section
    UseHCPCS codes correspond to radiotracers used for non‑oncologic PET imaging
    NoteS8085 is flagged E/I in the policy for an experimental FDG dual‑head coincidence technique
    CMS cardiac PET NCDs — referenced national coverage decisions
    CMS cardiac PET NCD referencesPolicy references CMS NCDs for PET perfusion of the heart (NCD 220.6.1) and FDG PET for myocardial viability (NCD 220.6.8)
    ImplicationPolicy aligns certain cardiac PET indications with existing CMS national coverage decisions
    VerificationProviders should verify Medicare/local coverage when applicable

    Prior Authorization Guidance and Frequency Limits

    Prior Authorization

    Authorization for repeat cardiac sarcoidosis PET at 3–6 months

    Repeated PET for active cardiac sarcoidosis may be authorized at 3–6 month intervals; obtain authorization consistent with this frequency limit when applicable.

    Prior Authorization

    AQMBF requires concurrent cardiac PET perfusion for authorization

    AQMBF is medically appropriate only when performed together with cardiac PET perfusion; prior authorization should reflect that AQMBF is an add‑on to PET perfusion.

    Prior Authorization

    Prior auth when ETT inconclusive/abnormal—submit ETT findings

    When ETT is inconclusive or shows specified abnormal results (e.g., failure to reach 85% MPHR, ST depression ≥ 1.0 mm, CAC ≥ 100), prior authorization for PET may be required and documentation of the ETT findings should be submitted.

    Prior Authorization

    Prior auth for PET before/while on Class IC antiarrhythmics

    Obtain prior authorization for PET performed prior to initiating or annually while on Class IC antiarrhythmics per plan rules.

    Prior Authorization

    Prior auth: FDG PET/CT for bone infection after equivocal MRI/CT

    Prior authorization is required for FDG PET/CT for suspected bone infection only after MRI or CT are equivocal or cannot be done and a qualifying indication (e.g., multifocal infection) is present.

    Prior Authorization

    Prior auth for PET/CT as alternative to nondiagnostic MRA/CTA

    Prior authorization is expected for PET/CT when used as an alternative to nondiagnostic MRA/CTA or for initial staging in place of MRA/CTA for suspected diffuse large‑vessel involvement; document prior nondiagnostic vascular imaging.

    Prior Authorization

    Prior auth: whole‑body FDG‑PET/CT for suspected spinal infection

    Prior authorization is required when whole‑body FDG‑PET/CT is requested for suspected spinal infection if MRI cannot be performed or is inconclusive and x‑ray/CT are abnormal; include documented risk factors or laboratory markers of infection.

    Prior Authorization

    Prior auth required for musculoskeletal PET/CT when MRI/CT equivocal

    Prior authorization is required for PET/CT in musculoskeletal indications when MRI or CT are equivocal or unavailable; submit documentation of prior imaging and clinical indication.

    Prior Authorization

    Verify authorization requirements for listed PET/PET‑CT codes

    Verify plan rules and authorization requirements for the PET/PET‑CT codes listed in the policy prior to performing services, as coverage and authorization requirements may vary by product.

    Repeat interval for cardiac sarcoidosis monitoring noted as 3-6 months (frequency limit guidance)
    Repeat interval for cardiac sarcoidosis monitoring3–6 months
    UsePET (FDG metabolic with perfusion) can be repeated at these intervals if active disease or to inform therapy decisions
    Prior authorization noteRepeated studies may be authorized at 3–6 month intervals for active cardiac sarcoidosis
    PET/CT surveillance interval example — every 2 years referenced for certain asymptomatic surveillance contexts
    PET/CT surveillance interval exampleEvery 2 years
    ContextExample frequency limit cited for asymptomatic individuals with prior silent ischemia
    UseApplies to routine surveillance rather than active disease monitoring

    Contrast and Radiotracer Considerations

    Billing Rule

    Radiotracer operational and contrast rules

    Many PET radiotracers require on‑site cyclotron production because of short half‑lives; exceptions include fluorine‑18 and rubidium‑82. Follow radiotracer operational and contrast rules when scheduling and billing studies.

    Background and Scope

    PET/CT may be used in several non-oncologic abdominal and cardiac contexts to assess metabolic activity when conventional imaging or biopsy is nondiagnostic or infeasible. Common non-oncologic uses include evaluation to guide biopsy in lymphoproliferative disorders, assessment of indeterminate splenic or mesenteric disease, and cardiac PET for perfusion, viability, or inflammatory conditions such as cardiac sarcoidosis.

    Not Covered / Investigational Indications

    The policy lists multiple not-covered or investigational uses including PET/CT for pulmonary ground-glass opacities (ground-glass nodules are excluded from the incidental pulmonary nodule indication), PET for impotence/erectile dysfunction (investigational), PET/CT for evaluation of Gaucher disease (not medically appropriate), and routine PET/CT for non-neoplastic spinal disorders or routine post‑surgical spine assessment (not medically appropriate). These scenarios may be denied if submitted for coverage.

    Revision History and Policy Changes

    2026-06-18committee_approvalLatest

    Off-cycle review added new criteria for Absolute Quantitation Of Myocardial Blood Flow (AQMBF) with PET and for stress testing with imaging including PET MPI.

    2026-01-22policy_revision_added

    Abdominal PET/CT: added medically appropriate criteria for sclerosing mesenteritis, incidental non-diagnostic splenic findings, and retroperitoneal fibrosis.

    2026-01-22policy_revision_added

    Chest PET/CT: added indications for mediastinal lymphadenopathy and for incidental pulmonary nodule detected by CT.

    2026-01-22policy_restructure

    Removed all head imaging criteria from this policy and moved them to PET Head Imaging Policy #6.01.47.

    2026-01-22policy_revision_added

    Spine PET/CT: added a new medically appropriate statement for FDG-PET/CT whole-body imaging for suspected spinal infections when prior imaging is equivocal or cannot be performed and listed clinical criteria are met.

    2026-01-22policy_revision_added

    Peripheral vascular disease (PVD) PET/CT: added medically necessary statement allowing PET/CT for initial staging in place of MRA or CTA of multiple areas when diffuse large-vessel involvement is suspected.

    The policy's HCPCS listing includes code S8085 with an (E/I) designation indicating experimental/investigational status. Experimental codes flagged in the policy should be considered when assessing coverage and prior authorization, as such items may not be covered.

    see nodes

    All conditions must be met.